The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | The influence of bridging therapy on outcomes in large B-cell lymphoma
Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, discusses the use of bridging therapy in a real world setting for patients with large B-cell lymphoma (LBCL) receiving axicabtagene ciloleucel (axi-cel), a chimeric antigen receptor (CAR) T-cell therapy. Stabilization of disease prior to treatment is associated with improved patients outcomes, independent of type of bridging therapy. However, investigational use of polatuzumab vedotin with rituximab and bendamustine as bridging therapy did not result in superior outcomes compared to other bridging regimens. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
